EHA2026レポート③ Late-breaking Session

再発・難治性多発性骨髄腫で、Kd療法への
mezigdomide追加によりPFSが有意に改善 Mezigdomide, carfilzomib, and dexamethasone vs carfilzomib and dexamethasone in relapsed/ refractory multiple myeloma: results from the phase 3 SUCCESSOR-2 trial (#LB5004)

Meletios A. Dimopoulos（Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece）